Mesoblast, Inc.

This study tested a single injection of special stem cells (Rexlemestrocel-L) into the heart for people with chronic heart failure. The goal was to see if it could reduce serious heart events like hospitalizations or death. The trial involved 565 adults and compared the stem cell…

This study looked at the safety of giving repeated doses of remestemcel-L, a stem cell therapy, to 73 people with moderate-to-severe Crohn's disease that didn't respond to standard treatments. Participants had already received the drug in an earlier study and were given three mor…

This study tested a single intravenous infusion of stem cells (PROCHYMAL) in 220 adults who had their first heart attack within the prior week. The goal was to see if the treatment could safely improve heart function, as measured by MRI scans at 3 months. Participants were random…

This phase 3 trial tested a stem cell treatment called PROCHYMAL in 98 people with moderate-to-severe Crohn's disease who had already responded to an earlier stem cell dose. The goal was to see how long the benefit lasts and whether a repeat dose can bring back symptom relief. Pa…

This phase 2 trial tested whether infusions of PROCHYMAL, a stem cell product, could safely help people recently diagnosed with type 1 diabetes. The study enrolled 63 participants aged 12–35 who had been diagnosed within the past 20 weeks. Researchers measured how well the pancre…

This phase 3 trial tests whether infusions of PROCHYMAL, a type of adult stem cell, can help people with moderate-to-severe Crohn's disease who haven't responded to standard treatments. Over 300 participants will receive either stem cells or a placebo through an IV four times ove…

This phase 2 trial tested whether infusions of PROCHYMAL, a stem cell product, are safe and can help people with moderate to severe COPD. 62 participants received either stem cells or a placebo. The main goal was to check for side effects, and researchers also looked at changes i…

This phase 2 study tested a stem cell product called Prochymal in 11 patients with severe graft-versus-host disease (GVHD) that did not improve with standard treatments. The goal was to see if the infusion could reduce or resolve GVHD symptoms by day 28. The study measured comple…